News Precigen, Inc.

Equities

PGEN

US74017N1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.4 ^USD	-1.41%		+6.06%	+4.48%

Apr. 24	Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	CI
Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting	Apr. 25	AQ
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	Apr. 24	CI
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th	Mar. 28	PR
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Precigen Shares Fall After Downgrade From JPMorgan	Mar. 22	MT
JPMorgan Downgrades Precigen to Underweight From Neutral	Mar. 22	MT
Precigen Reports Full Year 2023 Financial Results and Business Updates	Mar. 20	AQ
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Transcript : Precigen, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	Mar. 12	PR
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th	Mar. 05	PR
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	PR
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe	Jan. 16	MT
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	Jan. 16	PR
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	Jan. 16	CI
Transcript : Precigen, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 09	AQ
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 18	PR
Precigen to Participate in the JMP Securities Hematology and Oncology Summit	Nov. 29	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Precigen, Inc.

Equities

PGEN

US74017N1054

Summary

Filters